On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi  (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...

Sanofi SA (SNY) reports a robust 16% sales increase, driven by Dupixent and vaccines, while navigating market challenges and ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

October 25, 2024. More for You. Notable People who died in 2024 ...